Clinical trial
An Early Phase II Trial for Efficacy and Safety of TTA-121 on Autism Spectrum Disorder
NCT03466671 is registered in ClinicalTrials.gov with Hamamatsu University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Early Phase II Trial for Efficacy and Safety of TTA-121 on Autism Spectrum Disorder
- Lead sponsor
- Hamamatsu University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- February 27, 2018
- Completion date
- March 30, 2020
- Enrollment
- 144 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.